NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LAMIVUDINE; ZIDOVUDINE is a fixed-dose oral tablet combination of two nucleoside reverse transcriptase inhibitors (NRTIs) indicated for HIV treatment. This combination targets HIV replication by inhibiting reverse transcriptase, a key viral enzyme. The product is currently in pre-launch stage under sponsorship by Matrix Surgical USA.
PRE_LAUNCH
Pre-launch status indicates early-stage commercial development; team size and investment will scale upon approval and market entry.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Joining this team at pre-launch offers exposure to HIV market dynamics and fixed-dose combination strategy, though commercial scale will depend on regulatory approval and market uptake. Career growth is tied to successful launch execution and competitive positioning in a mature therapeutic category.
Brand ManagerMedical Science Liaison
Worked on LAMIVUDINE; ZIDOVUDINE at Matrix Surgical USA? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.